In Vitro Activity of Cefepime-Zidebactam, Ceftazidime-Avibactam, and Other Comparators against Clinical Isolates of Enterobacterales , Pseudomonas aeruginosa, and Acinetobacter baumannii: Results from China Antimicrobial Surveillance Network (CHINET) in 2018-Reference-Cited by-同舟云学术

In Vitro Activity of Cefepime-Zidebactam, Ceftazidime-Avibactam, and Other Comparators against Clinical Isolates of Enterobacterales , Pseudomonas aeruginosa, and Acinetobacter baumannii: Results from China Antimicrobial Surveillance Network (CHINET) in 2018

Published:2020-12-16 Issue:1 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Yang Yang¹²,Guo Yan¹²,Yin Dandan¹²,Zheng Yonggui¹²,Wu Shi¹²,Zhu Demei¹²,Hu Fupin¹²^ORCID

Affiliation:

1. Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China

2. Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China

Abstract

This study evaluated the in vitro activity of cefepime-zidebactam in comparison with that of ceftazidime-avibactam and other comparators against clinically significant Gram-negative bacillus isolates. A total of 3,400 nonduplicate Gram-negative clinical isolates were collected from 45 medical centers across China in the CHINET Program in 2018, including Enterobacterales ( n = 2,228), Pseudomonas aeruginosa ( n = 657), and Acinetobacter baumannii ( n = 515).

Funder

National Natural Science Foundation of China

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01726-20

Reference21 articles.

1. Centers for Disease Control and Prevention. 2019. AR threats report. https://www.cdc.gov/drugresistance/biggest-threats.html#carp.

2. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

3. In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens

4. New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship

5. Actavis. 2015. AVYCAZ (ceftazidime-avibactam) for injection for intravenous use. Initial U.S. approval: 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206494s000lbl.pdf.

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ceftolozane/tazobactam: Literature review of its activity on Taiwanese isolates before its launch in Taiwan (2012–2021);Heliyon;2024-07

2. Phage-induced efflux down-regulation boosts antibiotic efficacy;PLOS Pathogens;2024-06-28

3. Transmission of ceftazidime-avibactam-resistant Escherichia coli among pets, veterinarians and animal hospital environment;Biosafety and Health;2024-06

4. Friends or foes? Novel antimicrobials tackling MDR/XDR Gram-negative bacteria: a systematic review;Frontiers in Microbiology;2024-05-10

5. The microbiome, resistome, and their co-evolution in sewage at a hospital for infectious diseases in Shanghai, China;Microbiology Spectrum;2023-12-22